Skip to content
10-Q

Quarterly Report

Beam Therapeutics Inc. BEAM

0000950170-25-063966

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 29, 2025 100.56M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $141.55M
Current Liabilities Q1 2025 · Dec 31, 2024 $182.07M
Total Liabilities Q1 2025 · Mar 31, 2025 $343.78M
Total Liabilities Q1 2025 · Dec 31, 2024 $370.28M
Current Assets Q1 2025 · Mar 31, 2025 $1.25B
Current Assets Q1 2025 · Dec 31, 2024 $878.15M
Total Assets Q1 2025 · Mar 31, 2025 $1.47B
Total Assets Q1 2025 · Dec 31, 2024 $1.1B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $281.97M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $287.85M
Shares Diluted Q1 2025 · Mar 31, 2024 81.7M sh
Capex Q1 2025 · Mar 31, 2024 $2.44M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$99.75M
Stockholders Equity Q1 2025 · Mar 31, 2024 $913.49M
Stockholders Equity Q1 2025 · Dec 31, 2023 $981.33M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.21
Eps Basic Q1 2025 · Mar 31, 2024 −$1.21
Sga Expense Q1 2025 · Mar 31, 2024 $26.72M
Rd Expense Q1 2025 · Mar 31, 2024 $84.82M
Net Income Q1 2025 · Mar 31, 2024 −$98.67M
Operating Income Q1 2025 · Mar 31, 2024 −$104.13M
Revenue Q1 2025 · Mar 31, 2024 $7.41M